Design of a prognostic index score for metastatic nasopharyngeal carcinoma
- PMID: 12855259
- DOI: 10.1016/s0959-8049(03)00310-1
Design of a prognostic index score for metastatic nasopharyngeal carcinoma
Abstract
The survival outcome of patients with systemic cancer differs significantly between individuals even within the same tumour type. We set out to illustrate this by analysing the factors determining survival in patients with metastatic disease from nasopharyngeal carcinoma (NPC) and to design a scoring system based on these prognostic factors. Patients referred between January 1994 and December 1999 were retrospectively analysed. Factors analysed included patient (age group, gender, performance status (BS) at diagnosis of metastases), disease (number of metastatic sites, specific metastatic sites, disease-free interval (DFI), metastases at presentation, presence of locoregional recurrence), and laboratory factors (leucocyte count, haemoglobin level, albumin level). Univariate and multivariable analyses were performed using the Cox proportion hazards model. A numerical score was derived from the regression coefficients of each independent prognostic variable. The prognostic index score (PIS) of each patient was calculated by totalling up the scores of each independent variable. Independently significant, negative prognostic factors were liver metastasis, lung metastasis, anaemia, poor PS, distant metastasis at initial diagnosis, and a DFI of <6 months. Three prognostic groups based on the PIS were obtained: (i) good risk (PIS=0-6); (ii) intermediate risk (7-10); (iii) poor risk (>or=11). The median survivals for these groups were 19.5, 10, and 5.8, months, respectively, (log rank test: P<0.0001). The variable prognosis of patients with disseminated NPC can be assessed by using easily available clinical information (patient, disease and laboratory factors). The PIS system will need to be validated on prospectively collected data of another cohort of patients.
Similar articles
-
To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area.Eur J Cancer. 2012 Apr;48(6):882-8. doi: 10.1016/j.ejca.2011.09.004. Epub 2011 Oct 24. Eur J Cancer. 2012. PMID: 22030451
-
Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma.Br J Cancer. 2005 Apr 25;92(8):1382-7. doi: 10.1038/sj.bjc.6602525. Br J Cancer. 2005. PMID: 15812546 Free PMC article.
-
Prognostic factors in metastatic nasopharyngeal carcinoma.Cancer Radiother. 2007 Dec;11(8):461-4. doi: 10.1016/j.canrad.2007.06.006. Epub 2007 Aug 3. Cancer Radiother. 2007. PMID: 17689126
-
Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment?Oral Oncol. 2011 Aug;47(8):747-52. doi: 10.1016/j.oraloncology.2011.05.010. Epub 2011 Jun 12. Oral Oncol. 2011. PMID: 21665523
-
Prognostic factors and survival in metastatic breast cancer: A single institution experience.Rep Pract Oncol Radiother. 2013 Feb 14;18(3):127-32. doi: 10.1016/j.rpor.2013.01.001. Rep Pract Oncol Radiother. 2013. PMID: 24416543 Free PMC article. Review.
Cited by
-
A novel statistical prognostic score model that includes serum CXCL5 levels and clinical classification predicts risk of disease progression and survival of nasopharyngeal carcinoma patients.PLoS One. 2013;8(2):e57830. doi: 10.1371/journal.pone.0057830. Epub 2013 Feb 28. PLoS One. 2013. PMID: 23469080 Free PMC article.
-
Prognostic model and optimal treatment for patients with stage IVc nasopharyngeal carcinoma at diagnosis.Sci Rep. 2019 Dec 17;9(1):19272. doi: 10.1038/s41598-019-55586-w. Sci Rep. 2019. PMID: 31848409 Free PMC article. Clinical Trial.
-
A nonendemic analysis of the patterns and prognosis of de novo metastatic nasopharyngeal carcinomas in older patients aged ≥ 65 years.Sci Rep. 2022 May 18;12(1):8321. doi: 10.1038/s41598-022-12368-1. Sci Rep. 2022. PMID: 35585123 Free PMC article.
-
Intensive Local Radiotherapy Is Associated With Better Local Control and Prolonged Survival in Bone-Metastatic Nasopharyngeal Carcinoma Patients.Front Oncol. 2020 Mar 20;10:378. doi: 10.3389/fonc.2020.00378. eCollection 2020. Front Oncol. 2020. PMID: 32266152 Free PMC article.
-
Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update.Transl Oncol. 2018 Apr;11(2):286-291. doi: 10.1016/j.tranon.2018.01.002. Epub 2018 Feb 3. Transl Oncol. 2018. PMID: 29413761 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources